Logo

Samsung Bioepis Presents Five-Year Follow-Up Results of SB3 (biosimilar, trastuzumab) in P-III Study for Breast Cancer at SABCS 2021

Share this
Samsung Bioepis Presents Five-Year Follow-Up Results of SB3 (biosimilar, trastuzumab) in P-III Study for Breast Cancer at SABCS 2021

Samsung Bioepis Presents Five-Year Follow-Up Results of SB3 (biosimilar, trastuzumab) in P-III Study for Breast Cancer at SABCS 2021

Shots:

  • The company reported the 5yr. follow up results of P-III study evaluating SB3 (trastuzumab biosimilar) vs trastuzumab in 875 patients with HER2-positive early or LA breast cancer for 4yrs. post randomization
  • The results showed comparable long-term survival results b/w SB3 and trastuzumab after a median follow-up of 68mos. In 5yrs. survival analysis, EFS rate (79.8% & 75.0%), 5yrs. OS was also comparable with OS rate (92.5% & 85.4%)
  • In the post-hoc analysis, SB3 was compared with non-drifted trastuzumab which showed an EFS rate (79.8% vs 82.5%), OS rate (92.5% & 91.4%). SB3 was approved in the US under the brand name Ontruzant & is marketed by Organon

Ref: Globe Newswire | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions